A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

August 8, 2025

Study Completion Date

September 3, 2025

Conditions

Healthy Participants

Interventions

DRUG

Immunoglobulin G

Participants will receive SC administrations of IgG

Trial Locations (3)

Daytona Beach Clinical Rsch Unit, Daytona Beach

Fortrea Clinical Research Unit - Dallas, Dallas

Fortrea Clinical Research Unit Inc. - Madison, Madison